EUVIMEDEUVIMED entdecken
Open Access

Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections

Andrew S Haynes iD, Zixuan Wei, Peter Anderson, Marc H Scheetz iD, Sarah K Parker, Douglas N Fish

Antimicrobial Agents and Chemotherapy · 02.05.2024 · 68 (5)

DOI: 10.1128/aac.00182-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.05.2024. Verfasst von Andrew S Haynes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital Colorado, Department of Pediatrics, Section of Pediatric Infectious Diseases, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Cephalexin, Anti-Bacterial Agents, Cefadroxil, Microbial Sensitivity Tests. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cephalexin, a first-generation cephalosporin, is the first-line oral therapy for children with musculoskeletal infections due to methicillin-susceptible Staphylococcus aureus (MSSA). Cefadroxil, a similar first-generation cephalosporin, is an attractive alternative to cephalexin given its longer half-life. In this study, we describe the comparative pharmacokinetics (PK) and pharmacodynamics (PD) of cephalexin and cefadroxil in children with musculoskeletal infections. Children aged 6 months to 18 years with a musculoskeletal infection were enrolled in a prospective, open-label, crossover PK study and given single oral doses of cefadroxil (50–75 mg/kg up to 2,000 mg) and cephalexin (50 mg/kg up to 1,375 mg). Population PK models were developed and used for dosing simulations. Our primary PD target was the achievement of free antibiotic concentrations above the minimum inhibitory concentration ( f T >MIC) for 40% of the day for MICs ≤ 4 mg/L. PK of cephalexin ( n = 15) and cefadroxil ( n = 14) were best described using a one-compartment, first-order absorption model, with a lag time component for cefadroxil. PK parameters were notable for cefadroxil’s longer half-life (1.61 h) than cephalexin’s (1.10 h). For pediatric weight bands, our primary PD target was achieved by cephalexin 25 mg/kg/dose, maximum 750 mg/dose, administered three times daily and cefadroxil 40 mg/kg/dose, maximum 1,500 mg/dose, administered twice daily. More aggressive dosing was required to achieve higher PD targets. Among children with musculoskeletal infections, oral cephalexin and cefadroxil achieved PD targets for efficacy against MSSA. Given less frequent dosing, twice-daily cefadroxil should be further considered as an alternative to cephalexin for oral step-down therapy for serious infections due to MSSA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CephalexinAnti-Bacterial AgentsCefadroxilMicrobial Sensitivity TestsCross-Over StudiesHumansChildFemaleMaleChild, PreschoolAdolescentInfantProspective StudiesStaphylococcal InfectionsStaphylococcus aureus

Stichwörter der Autor:innen

cefadroxilcephalexinosteomyelitispediatric drug therapypediatric infectious diseasepharmacodynamicspharmacokinetics

Substanzen

CephalexinAnti-Bacterial AgentsCefadroxil

Autor:innen und Institutionen

  • Children's Hospital Colorado, Department of Pediatrics, Section of Pediatric Infectious Diseases, Aurora, Colorado, USA.
  • University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, Colorado, USA.
  • University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
  • Midwestern University, Pharmacometrics Center of Excellence, Colleges of Pharmacy and Pharmacology, Downers Grove, Illinois, USA.

ORCID-Profile: Andrew S Haynes, Marc H Scheetz

Förderung

  • NICHD NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • HHS | NIH | National Center for Advancing Translational Sciences
  • Children's Hospital Colorado Research Institute

Zitieren

APA

Haynes, A. S., Wei, Z., Anderson, P., Scheetz, M. H., Parker, S. K., & Fish, D. N. (2024). Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections. Antimicrobial Agents and Chemotherapy, 68(5). https://doi.org/10.1128/aac.00182-24

Vancouver

Haynes AS, Wei Z, Anderson P, Scheetz MH, Parker SK, Fish DN. Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections. Antimicrobial Agents and Chemotherapy. 2024;68(5). doi:10.1128/aac.00182-24

BibTeX
@article{Haynes2024,
  author = {Haynes, Andrew S and Wei, Zixuan and Anderson, Peter and Scheetz, Marc H and Parker, Sarah K and Fish, Douglas N},
  title = {Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {5},
  doi = {10.1128/aac.00182-24}
}
Kostenlos starten →